Next Article in Journal
Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
Next Article in Special Issue
Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors
Previous Article in Journal
The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)—A Protocol for an International Cohort Study
Previous Article in Special Issue
Survival Outcomes in Invasive Lobular Carcinoma Compared to Oestrogen Receptor-Positive Invasive Ductal Carcinoma
Commentary

How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research

1
Lobular Breast Cancer Alliance, Breast Cancer Advocate, Seattle, WA 98117, USA
2
Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, 3000 Leuven, Belgium
3
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
4
Lobular Breast Cancer Alliance, Plymouth, MA 02360, USA
5
Lobular Breast Cancer UK, UK Patient Advocate Representative for European Lobular Breast Cancer Consortium, Manchester, Greater Manchester M32 8PA, UK
6
European Lobular Breast Cancer Consortium, Y25HP26 Dublin, Wexford, Ireland
7
Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA
8
Magee Women’s Research Institute, Pittsburgh, PA 15213, USA
9
UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Esta Sterneck
Cancers 2021, 13(13), 3094; https://doi.org/10.3390/cancers13133094
Received: 6 May 2021 / Revised: 15 June 2021 / Accepted: 16 June 2021 / Published: 22 June 2021
This commentary reflects a collaborative effort between international Invasive Lobular Carcinoma (ILC)-focused breast cancer researchers, clinicians and patient advocate leaders. It offers a perspective on the progress made in ILC research in recent years and discusses the recent rise in patient advocate involvement to advance ILC research, raise awareness and educate about this disease. It outlines several distinct challenges in conducting ILC research and describes opportunities and suggestions for ways researchers, clinicians and advocates can work together to advance ILC research to develop new therapies and refine the care offered to patients.
Breast cancer research and therapies have significantly advanced in recent years. However, Invasive Lobular Carcinoma (ILC), the second most common histological type of breast cancer and the sixth most frequently diagnosed cancer of women, has not always benefited from critical analysis, missing opportunities to better understand this important subtype. Recent progress understanding the biological and behavioral differences of ILC demonstrates that it is a unique subtype of breast cancer which can respond differently to common therapies. These new insights have increased interest in researching lobular breast disease. Concurrently, the formation of motivated patient-led advocacy organizations working in partnership with basic, translational and clinical researchers creates new opportunities, including connecting a dispersed patient population to research, encouraging new research funding and connecting patient advocates to researchers to advance common goals. This commentary will explore the unprecedented opportunity to drive multidisciplinary, multicenter and international collaborative research into lobular breast cancer that builds on recent research progress. Collaborative research partnerships that include advocates can result in a better understanding of ILC, identify targeted therapies and refine standard of care therapies that are currently equally applied to all breast cancers, resulting in improvements in the diagnosis, treatment and follow-up care for patients with ILC. View Full-Text
Keywords: breast cancer; lobular; ductal; invasive lobular carcinoma; ILC; patient advocacy; advocacy; research advocacy breast cancer; lobular; ductal; invasive lobular carcinoma; ILC; patient advocacy; advocacy; research advocacy
Show Figures

Figure 1

MDPI and ACS Style

Pate, L.; Desmedt, C.; Metzger, O.; Burgess Hutcheson, L.; Turner, C.; Freeney, S.; Oesterreich, S. How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research. Cancers 2021, 13, 3094. https://doi.org/10.3390/cancers13133094

AMA Style

Pate L, Desmedt C, Metzger O, Burgess Hutcheson L, Turner C, Freeney S, Oesterreich S. How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research. Cancers. 2021; 13(13):3094. https://doi.org/10.3390/cancers13133094

Chicago/Turabian Style

Pate, Leigh, Christine Desmedt, Otto Metzger, Laurie Burgess Hutcheson, Claire Turner, Siobhán Freeney, and Steffi Oesterreich. 2021. "How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research" Cancers 13, no. 13: 3094. https://doi.org/10.3390/cancers13133094

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop